zihan Ding

Dr. zihan Ding


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2025 in Social Science & Medicine
Verified
Journal Article
Open access
WZWu Zhou
Wu Zhou
BHBo Hei
Bo Hei
ZLZhixin Liu
Zhixin Liu
YLYihao Liu
Yihao Liu
ZDzihan Ding
zihan Ding
MLMeihua Li
Meihua Li
This study examines global trends in depression incidence among women of childbearing age (WCBA) from 1992 to 2021 and projects future trends through 2030. Using data from the Global Burden of Disease (GBD) 2021 and applying the age-period-cohort (APC) model, we analyzed temporal patterns across age groups, periods, and birth cohorts. The global incidence of depression in WCBA increased from 77.57 million cases in 1992 to 127.02 million cases in 2021, with the age-standardized incidence rate (ASIR) rising from 5675.52 to 6490.04 per 100,000 people. The estimated annual percentage change (EAPC) was -0.21 (95 % CI: 0.47 to 0.06), indicating a slight, non-significant decline. Regional disparities were evident: high SDI regions saw rising depression incidence, while other regions experienced declines. Notably, in high SDI regions, depression incidence decreased in the 30-34 age group but increased in other age groups. In contrast, in other SDI regions, depression incidence decreased across all age groups. APC analysis across the four SDI regions (excluding the high SDI region) revealed distinct age, period, and cohort effects on depression incidence in WCBA. The age effect was consistent globally and across SDI regions, with depression incidence increasing with age. However, in high SDI regions, the age effect showed a contrasting trend, with notable adverse period and cohort effects. These findings highlight the need for targeted interventions and further research to mitigate the growing mental health burden, particularly in women of reproductive age, in alignment with the WHO's 2030 objectives.


8 April 2025 in World Neurosurgery
Verified
Journal Article
Open access
CLChengcai Li
Chengcai Li
JWJiwei Wang
Jiwei Wang
WLWei Liu
Wei Liu
ZWZan Wang
Zan Wang
XLXiaojuan Luo
Xiaojuan Luo
ZDzihan Ding
zihan Ding
This study aimed to explore the relationship between intramedullary injury and midsagittal tissue bridges at the epicenter of subacute traumatic cervical spinal cord injury (SCI) and long-term clinical recovery. Imaging and clinical data from 57 traumatic cervical SCI patients at the First Affiliated Hospital of Nanchang University were retrospectively assessed. Midsagittal T2-weighted scans at 1 month postinjury were used to quantify lesion size and tissue bridge width. Correlation analyses were performed to determine the association among tissue bridge width, lesion size, and long-term clinical recovery. At 1 month after SCI, ventral midsagittal tissue bridges (VMTB), dorsal midsagittal tissue bridges (DMTB), and total midsagittal tissue bridges (TMTB) were associated with better American spinal injury association Impairment Scale grades at 1 year postinjury. Shorter intramedullary lesion length (IMLL) and smaller intramedullary lesion width (IMLW) were linked to better outcomes. TMTB exhibited a stronger correlation with improved American spinal injury association Impairment Scale grades compared to VMTB, DMTB, IMLL, and IMLW. Moreover, IMLL and IMLW were significantly higher, while the DMTB, VMTB, and TMTB widths were significantly lower in patients with a poor prognosis than in those with a good prognosis. Receiver operating characteristic analysis showed TMTB had better predictive performance than other measures. The observed association between clinical prognosis and midsagittal tissue bridges underscores the clinical relevance of these structures as neuroimaging biomarkers in patients with subacute SCI. Thus, midsagittal tissue bridges may serve as promising and reliable magnetic resonance imaging biomarkers during the transition from acute to chronic phase for stratifying, treating, and evaluating patient subgroups in clinical trials.